Study to Evaluate Safety and Activity of TRL1068 in Chronic Rhinosinusitis

NCT ID: NCT05355207

Last Updated: 2023-04-12

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-31
• Study Completion Date: 2025-01-31

Brief Summary

TRL1068 is expected to eliminate the pathogen-protecting biofilm in Chronic Rhinosinusitis, thus making these bacteria substantially more susceptible to established antibiotic treatment regimens. This initial study is to assess overall safety and pharmacokinetics (PK) of TRL1068. The goal of the development program is to demonstrate effectiveness of TRL1068 in difficult to treat bacterial infections such as in CRS.

Detailed Description

Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and decreased quality of life. Defects in the epithelial cell barrier, increased exposure to pathogenic and colonized bacteria, and dysregulation of the host immune system are all thought to play prominent roles in disease pathogenesis. Colonization with S. aureus or P. aureus are associated with recalcitrant disease and biofilm formation, making eradication difficult.

Distribution of topical solutions in the unoperated sinuses has been observed to be less than 2% of the total irrigation volume, with almost no penetration in the frontal and sphenoid sinuses. For those patients with mucosal edema from infection and chronic inflammation, distribution is probably significantly less when applied topically. Intravenously administered TRL1068 is expected to achieve effective anti-biofilm levels throughout the sinonasal space for several weeks. TRL1068 is a monoclonal human antibody that rapidly eliminates biofilm at very low concentrations, thus making the targeted bacterial pathogens substantially more sensitive to standard of care antibiotic treatment regimen and greatly accelerating clinical improvement and potential for bacterial eradication.

Conditions

Chronic Rhinosinusitis With Nasal Polyps

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TRL1068

all subjects will receive a single intravenous dose of 15 mg/kg of TRL1068 on Day 1

Group Type: EXPERIMENTAL

TRL1068

Intervention Type: DRUG

A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody

Interventions

TRL1068

A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age 18 to 85 years, inclusive

2. Diagnosis of chronic rhinosinusitis with:

1. Acute exacerbation of CRSwNP with increased sinonasal discharge OR

2. Acute exacerbation post-functional endoscopic sinus surgery (FESS) with increased sinonasal discharge AND

3. Sinonasal culture positive for SA or PA without concomitant fungal infection in culture or PCR

3. Symptoms and culture results justify initiation of topical and/or systemic antibiotic treatment

4. Willing and able to provide written informed consent

5. Willing to perform and comply with all study procedures including attending clinic visits as scheduled

6. Men and women of child bearing potential (WOCBP) must be willing to practice a highly effective method of contraception that may include, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with vasectomized partner, vasectomy, hysterectomy, bilateral tubal ligation, licensed hormonal methods, intrauterine device (IUD), or use of spermicide combined with a barrier method (e.g., condom, diaphragm) for 28 days before receiving the investigational product (IP) and through Day 50.

Exclusion Criteria

1. Active malignancy, or history of malignancy or chemotherapy within the past 2 years other than history of localized or surgical removal of focal skin cancer, or cervical cancer in situ treated successfully in the past by local treatment (including but not limited to cryotherapy or laser therapy) or by hysterectomy

2. Any chronic or acute bacterial infection other than acute exacerbation of CRS

3. Concomitant intrasinal culture or 16S PCR indicative of concomitant fungal infection

4. Allergic fungal rhinosinusitis, characterized by elevated antifungal IgE and eosinophilic mucus

5. Receiving or recently received another investigational drug (within 30 days of Day 1, or 5 half-lives of the investigational drug, whichever is longer)

6. Received a COVID-19 vaccine or booster within 14 days of planned Day 1 or planned COVID-19 vaccination within 14 days after Day 1

7. Positive serum test for pregnancy, pregnant, or nursing women

8. History of drug or alcohol abuse that, in the opinion of the Investigator, would interfere with the subject's ability to comply with the study requirements

9. Any other comorbidity or condition that, in the opinion of the Investigator would make the subject unsuitable for the study or unable to comply with the study requirements

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Trellis Bioscience LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Anton (Tony) Leighton, MD

Role: CONTACT

Clinicalstudies@trellisbio.com

650-838-1400

Adriane Kisch-Hancock

Role: CONTACT

akisch-hancock@trellisbio.com

650-838-1400

References

Estelles A, Woischnig AK, Liu K, Stephenson R, Lomongsod E, Nguyen D, Zhang J, Heidecker M, Yang Y, Simon RJ, Tenorio E, Ellsworth S, Leighton A, Ryser S, Gremmelmaier NK, Kauvar LM. A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2292-301. doi: 10.1128/AAC.02588-15. Print 2016 Apr.

Reference Type: BACKGROUND

PMID: 26833157 (View on PubMed)

Xiong YQ, Estelles A, Li L, Abdelhady W, Gonzales R, Bayer AS, Tenorio E, Leighton A, Ryser S, Kauvar LM. A Human Biofilm-Disrupting Monoclonal Antibody Potentiates Antibiotic Efficacy in Rodent Models of both Staphylococcus aureus and Acinetobacter baumannii Infections. Antimicrob Agents Chemother. 2017 Sep 22;61(10):e00904-17. doi: 10.1128/AAC.00904-17. Print 2017 Oct.

Reference Type: BACKGROUND

PMID: 28717038 (View on PubMed)

Other Identifiers

TRL1068-104

Identifier Type: -

Identifier Source: org_study_id